Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South America Brazil Coronavirus COVID-19

Brazilian Regulator Extends COVID-19 Measures

  • News

Executive Summary

Brazil’s medicines regulator is extending COVID-19 era resolutions designed to speed up its evaluation of clinical research in Brazil.

You may also be interested in...



Saudi Regulator Becomes First Arab Member Of PIC/S

Saudi Arabia’s medicines agency says its membership of the international Pharmaceutical Inspection Co-operation Scheme will contribute to developing and raising inspectors' efficiency.

France Trials Quicker Route To Patients For Innovative Medicines

France is piloting a new approach that will allow innovative products to be accessed by patients before a reimbursement price has been agreed.

EU Regulatory Reforms Mean Many Orphan Drug Producers Won’t Benefit From Incentives

The EU’s regulatory reform package if unchanged could make orphan drug development less attractive, warn industry representatives.

Table

View full table

Topics

Tags:
South America Brazil Coronavirus COVID-19
Latest Headlines

AstraZeneca/Sanofi’s Nirsevimab Nears US FDA Approval After Overwhelmingly Positive Adcomm

FDA’s Office Of Generic Drugs Gets New Permanent Director And Oversight Designee

Big Drug, Small Panel: US FDA Adcomm For Eisai/Biogen’s Leqembi Includes Only Six Voting Members

US FDA Balances Urgent Need For Platinum Chemotherapies Against Intas Plant’s Quality Failures

See All
UsernamePublicRestriction

Register

PS148263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By